Use of ultrahigh RAAS blockade: Implications for exacerbation of renal failure  by Onuigbo, M.A.C. & Onuigbo, N.T.C.
Activated parietal epithelial cells
or dedifferentiated podocytes in
FSGS: Can we make the
difference?
Kidney International (2006) 69, 194. doi:10.1038/sj.ki.5000069
To the Editor: Dijkman et al.1 did excellent work on a single
specimen of transplant nephrectomy for recurrent idiopathic
focal segmental glomerulosclerosis (FSGS): using immuno-
histochemical markers and three-dimensional (3D) recon-
struction of glomeruli, they characterized the lineage of cells
present in the FSGS lesions and concluded that proliferated
epithelial cells originate from parietal epithelial cells (PEC).
However, the possibility that these cells could, in fact, be
dedifferentiated podocytes cannot be ruled out. Indeed, PEC
and dedifferentiated podocytes share common phenotypes.
During nephrogenesis (reviewed by Pavensta¨dt et al.2 and
Kreidberg3), precursors of both podocytes and PEC express
the junctional protein P-cadherin, cytokeratins and PAX2.
During the maturation of glomeruli, collagen chain expres-
sion shifts from IVa1 and a2 to a3, a4 and a5 in the
glomerular basement membrane, and the podocytes acquire a
mature phenotype. They loose the expression of PAX2, which
is correlated with the loss of mitotic properties. They do no
longer express cytokeratins and acquire specific podocyte
proteins.
In the cellular variants of FSGS, the podocytes are
dysregulated and dedifferentiated.4,5 They proliferate, lose
their specific proteins, and again express markers of
immature podocytes as in fetal glomeruli. Thus, the
expression of P-cadherin, cytokeratins, PAX2, and IVa1 and
a2 collagens can be observed in dedifferentiated podocytes as
well as in PEC. In idiopathic FSGS, PAX2 (unpublished data)
and cytokeratins4 have been detected in podocytes, covering
the tuft in the absence of any synechia, particularly in the
collapsing variant of FSGS or in glomeruli where the
cytokeratin-negative PEC stand opposite to cytokeratin-
positive dedifferentiated podocytes. This indicates that
proliferated epithelial cells can be dedifferentiated podocytes
and not necessarily activated PEC migrated from the
Bowman’s capsule. In the study of Dijkman et al.,1 the
damaged glomeruli shown in 3D reconstruction exhibited
synechia between the tuft and capsule. Under this condition,
we suggest that cells from both origins (i.e. tuft podocytes
and capsular PEC) can easily be mixed and cannot be
specifically identified by the immunohistochemical markers
used.
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Use of ultrahigh RAAS blockade:
Implications for exacerbation of
renal failure
Kidney International (2006) 69, 194–195. doi:10.1038/sj.ki.5000068
To the Editor: Rossing et al.,1 lately, reported using
irbesartan, up to 900 mg/day, in 52 type II diabetic
microalbuminurics, compared to 300 mg/day, and showed
additional renoprotection.
Recently, concern has been raised of an increasing end-
stage renal disease epidemic in the USA, which was observed
to coincide with the increasing use of renin-angiotensin-
aldosterone system (RAAS) blockade.2 This raises a troubling
suspicion for iatrogenic end-stage renal disease.2
We recently reported a previously unrecognized syndrome
of late-onset renal failure from angiotensin blockade in
patients on stable doses of RAAS blockade.3 Mean serum
creatinine improved from 2.970.9 to 1.870.4 mg/dl
(P¼ 0.04) following discontinuation of RAAS blockade.3
We are very concerned about the potential implications of
the escalating and possibly uncontrolled use of ultrahigh
doses of RAAS blockade. The subjects were relatively young,
mean age 58 years, with normal baseline glomerular filtration
rate, mean 103 ml/min/1.73 m2.1 By contrast, the Antihyper-
tensive and Lipid-Lowering Treatment to prevent Heart
Attack Trial cohort of 33 357 patients was older, mean age 67
years, with lower mean baseline glomerular filtration rate,
78 ml/min/1.73 m2.4 Furthermore, treatment with irbesartan,
900 mg/day, was only for 2 months.1
The general applicability of such intense and overriding
total RAAS blocking strategies, particularly long term, and
more so in susceptible elderly diabetic hypertensives, with
lower glomerular filtration rates, is at the least very
troubling. Until we understand the long-term consequences
of such therapeutic maneuvers, strong caution must be
advised. Finally, we recommend more long-term monitoring
of kidney function in all patients on RAAS blockade, more so
in the susceptible elderly population.3
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Vascular calcification in chronic
kidney disease: Evolving
pathogenesis with progressive
chronic kidney disease?
Kidney International (2006) 69, 195. doi:10.1038/sj.ki.5000039
To the Editor: Cozollino and colleagues present a thoughtful
review on vascular calcification (VC) in chronic kidney
disease (CKD) and discuss the evidence supporting a
dominant role for disordered mineral metabolism in the
rapid progression of calcification seen in stage 5 CKD.1
However, the title and the article may lead one to conclude
that either VC is a major problem only in stage 5 CKD or that
disordered mineral metabolism plays a dominant role across
the entire spectrum of CKD. Accumulating evidence suggests
that VC is present in over 90% of diabetics (and is often quite
severe) and 40% of nondiabetics with CKD, long before stage
5 CKD or treatment with calcium-based phosphate binders,
and this appears to be unrelated to disordered mineral
metabolism.2,3 This observation is consistent with the
authors’ observations that phosphorus appears to induce
calcification only when its concentration in the culture media
exceeds 2.0 mmol/l – levels only rarely observed in stage 3 or 4
CKD. Finally, progression of VC is observed among diabetics
with CKD, over a rather short interval, long before stage 5
CKD, and this also appears to be independent of disordered
mineral metabolism.4
Thus, the available evidence suggests that VC begins and is
a significant problem early in CKD, and this is independent
of disordered mineral metabolism. Relatively rapid
progression of VC is demonstrable in nondialyzed diabetic
CKD, the process accelerates with worsening renal function
and disordered mineral metabolism likely assume a domi-
nant role quite late in the course of CKD (probably stage
4 or 5).
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